Skip to main content
Log in

GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript


Golgi protein-73 (GP73) is a newly identified candidate serum marker for HCC, but GP73 study now is lesser in Asian population. The aims of this study were to determine how GP73 is detected in the serum of healthy, hepatitis B, cirrhosis and HCC by western blotting and RT-PCR, and to establish the sensitivity and specificity of serum GP73 protein and RNA for diagnosing HCC. Serum GP73 was detected by western blotting and RT-PCR, and quantified by densitometric analysis. GP73 was measured in serum from 124 patients with various forms of liver. AFP was tested using commercially available electrochemiluminescence immunoassay. The median sGP73 in patients with HBV-related HCC was significantly higher (P < 0.001) than in healthy individuals and in patients with other diseases. When sGP73 protein was used to detect HBV-related HCC, it had a sensitivity of 77.4% and a specificity of 83.9%, at the optimal cut-off value of 7.4 relative units. The area under the receiver–operating characteristic curve was 0.89. GP73 RNA in patients with HBV-related HCC had a sensitivity of 87.1% and a specificity of 83.9% and AUROC of 0.92. AFP in patients with HCC had a sensitivity of 48.4% and a specificity of 96.8% and AUROC of 0.77. GP73 protein and RNA can be found in the serum of patients with HBV-related HCC obviously higher than of other liver diseases in Asian. GP73 was better than AFP for the diagnosis of HBV-related HCC. RT-PCR is a more sensitive and superior method of quantification than Western blot. Furthermore, our data need to be confirmed in larger cohorts of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others


  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74–108. doi:10.3322/canjclin.55.2.74.

    Article  PubMed  Google Scholar 

  2. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–14. doi:10.1053/j.gastro.2003.12.049.

    Article  PubMed  Google Scholar 

  3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17. doi:10.1016/S0140-6736(03)14964-1.

    Article  PubMed  Google Scholar 

  4. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 51):S113–9. doi:10.1053/j.gastro.2004.09.024.

    Article  CAS  PubMed  Google Scholar 

  5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–30. doi:10.1016/S0168-8278(01)00130-1.

    Article  CAS  PubMed  Google Scholar 

  6. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–8. doi:10.1002/hep.510270140.

    Article  CAS  PubMed  Google Scholar 

  7. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology. 1986;6:729–38. doi:10.1002/hep.1840060432.

    Article  CAS  PubMed  Google Scholar 

  8. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34:603–5. doi:10.1016/S0168-8278(01)00025-3.

    Article  CAS  PubMed  Google Scholar 

  9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36. doi:10.1002/hep.20933.

    Article  PubMed  Google Scholar 

  10. Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000;249:53–65. doi:10.1016/S0378-1119(00)00136-0.

    Article  CAS  PubMed  Google Scholar 

  11. Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma. Am J Gastroenterol. 2004;99:1096–8. doi:10.1111/j.1572-0241.2004.40410.x.

    Article  PubMed  Google Scholar 

  12. Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43:1007–12. doi:10.1016/j.jhep.2005.05.028.

    Article  CAS  PubMed  Google Scholar 

  13. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. 2005;41:634–42. doi:10.1002/hep.20577.

    Article  PubMed  Google Scholar 

  14. Iftikhar R, Kladney RD, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004;99:1087–95. doi:10.1111/j.1572-0241.2004.30572.x.

    Article  CAS  PubMed  Google Scholar 

  15. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35:1431–40. doi:10.1053/jhep.2002.32525.

    Article  CAS  PubMed  Google Scholar 

  16. Kladney RD, Tollefson AE, Wold WS, Fimmel CJ. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology. 2002;301:236–46. doi:10.1006/viro.2002.1523.

    Article  CAS  PubMed  Google Scholar 

  17. Chinese Society of Hepatology. 2004 Guidelines for surgical treatment of primary hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2005;13:329–30.

    Google Scholar 

  18. Chinese Society of Infectious Diseases. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2005;13:881–91.

    Google Scholar 

  19. Chinese Medical Association. Guideline of prevention and treatment of hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi. 2004;38:210–5.

    Google Scholar 

  20. Metz CEhB, Shen JH. Maximum-likelihood estimation of receiver operating characteristic (ROC) curves from continuously distributed data. Stat Med. 1998;17:1033–53. doi:10.1002/(SICI)1097-0258(19980515)17:9<1033::AID-SIM784>3.0.CO;2-Z.

    Article  CAS  PubMed  Google Scholar 

  21. Cassandra Willyard. Researchers look for ‘aweet’ method to diagnose cancer. Nat Med. 2007;13:1267. doi:10.1038/nm1107-1267.

    Article  PubMed  Google Scholar 

  22. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic. 2007;8:1415–23. doi:10.1111/j.1600-0854.2007.00621.x.

    Article  CAS  PubMed  Google Scholar 

  23. Lorinda MW, Sheri Y, Maria MP. Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol. 2009;2:34–47.

    Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to De-wu Wu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, Js., Wu, Dw., Liang, S. et al. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol 27, 339–345 (2010).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: